Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05937230
Other study ID # CAGE-FREE DM registry
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date June 1, 2015
Est. completion date March 1, 2026

Study information

Verified date October 2023
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Drug-eluting stents (DES) have long been recommended as the default device for patients undergoing percutaneous coronary intervention (PCI). Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel-coated on the balloon. DCB angioplasty has the following advantages compared to DES implantation: Firstly, the drug in DCB is uniformly distributed and released, whereas the drug release of DES via the stent platform is uneven -85% of the vascular wall is not covered by the stent strut. Secondly, there is no alloy in the vessel after DCB angioplasty, while the coronary stent platform and polymer might cause temporal or persistent inflammatory response leading to intimal hyperplasia. Finally, there is no metal cage restraining vessel motion after DCB, and the physiological function of coronary arteries would be maintained. Currently, DCB constitutes an important treatment option in ISR, which is endorsed by the 2018 European Society of Cardiology Guidelines on myocardial revascularization. In addition, some interventional cardiologist has also applied DCB in de novo lesions in their clinical practice. Diabetes is associated with worse outcomes after coronary revascularization and has been identified as an independent predictor of adverse events in patients with cardiovascular disease. Although some small sample size RCTs and observational studies have suggested that the clinical prognosis of DCB is non-inferior to the drug-eluting stent (DES), there is still a lack of evidence comparing the DCB versus DES for de novo or ISR coronary lesions in diabetic patients. The current study aims to compare the long-term efficacy of DCB to DES in de novo or ISR coronary lesions in diabetic patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1500
Est. completion date March 1, 2026
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with diabetes mellitus 2. Received PCI by a drug-coated balloons only strategy or drug-eluting stents only strategy Exclusion Criteria: 1. Under the age of 18 2. Unable to give informed consent 3. Currently participating in another trial or participants unable to comply to follow-up

Study Design


Intervention

Device:
Drug-coated balloon
Paclitaxel is a pharmacologically active substance for anti-neointima.
Drug-eluting stents
Drug-eluting stent is composed of a metal stent, primer, and drug coating.

Locations

Country Name City State
China Ling Tao Xi'an Shannxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other POCE POCE is a composite clinical endpoint of all-cause death, any stroke, non-fatal myocardial infarction (MI), any revascularization 1, 12, or 24 months
Other All-cause death Rates of individual components of PoCE 1, 12, or 24 months
Other Non-fatal myocardial infarction (MI) Rates of individual components of PoCE 1, 12, or 24 months
Other Any stroke Rates of individual components of PoCE 1, 12, or 24 months
Other Any revascularization Rates of individual components of PoCE 1, 12, or 24 months
Other Device-oriented Composite Endpoint (DoCE) Rates of the DoCE beside the time point of primary endpoint 1 or 12 months
Other Cardiac cause death Rates of individual components of the DoCE 1, 12, or 24 months
Other Target vessel myocardial infarction (TV-MI) Rates of individual components of the DoCE 1, 12, or 24 months
Other Clinically indicated target lesion revascularization (CI-TLR) Rates of individual components of the DoCE 1, 12, or 24 months
Other Target vessel failure (TVF) Target vessel failure, defined as cardiovascular death, TV MI and clinically-indicated target vessel revascularisation 1, 12, or 24 months
Primary Device-oriented Composite Endpoint (DoCE) DoCE is a composite clinical endpoint of Cardiac cause death, Target vessel myocardial infarction (TV-MI), and clinically indicated target lesion revascularization (CI-TLR). 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Completed NCT05088291 - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT04995159 - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System N/A
Recruiting NCT02967718 - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome N/A
Completed NCT02888652 - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Terminated NCT02045134 - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery N/A
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01920009 - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT02753829 - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Recruiting NCT01689688 - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography N/A
Completed NCT01779401 - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients N/A
Recruiting NCT01462799 - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care N/A
Recruiting NCT01456364 - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Phase 4
Completed NCT01428947 - Does Coronary Angiography Cause Cognitive Dysfunction? N/A